[A16-25] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Last updated 01.08.2016
Project no.:
A16-25
Commission:
Commission awarded on 02.05.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2016-10-20 A G-BA decision was published.